CN104364237B - 组蛋白去乙酰化酶(hdacs)抑制剂 - Google Patents

组蛋白去乙酰化酶(hdacs)抑制剂 Download PDF

Info

Publication number
CN104364237B
CN104364237B CN201380030630.7A CN201380030630A CN104364237B CN 104364237 B CN104364237 B CN 104364237B CN 201380030630 A CN201380030630 A CN 201380030630A CN 104364237 B CN104364237 B CN 104364237B
Authority
CN
China
Prior art keywords
dihydro
ethyl
oxo
compound
oxopropenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380030630.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104364237A (zh
Inventor
陈基旺
余兆武
张佩德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricky Biotechnology New Pharmaceutical Co ltd
Original Assignee
Annji Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharmaceutical Co Ltd filed Critical Annji Pharmaceutical Co Ltd
Publication of CN104364237A publication Critical patent/CN104364237A/zh
Application granted granted Critical
Publication of CN104364237B publication Critical patent/CN104364237B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380030630.7A 2012-04-10 2013-04-02 组蛋白去乙酰化酶(hdacs)抑制剂 Active CN104364237B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261622127P 2012-04-10 2012-04-10
US61/622,127 2012-04-10
PCT/US2013/035004 WO2013154870A1 (en) 2012-04-10 2013-04-02 Histone deacetylases (hdacs) inhibitors

Publications (2)

Publication Number Publication Date
CN104364237A CN104364237A (zh) 2015-02-18
CN104364237B true CN104364237B (zh) 2016-08-24

Family

ID=49292802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030630.7A Active CN104364237B (zh) 2012-04-10 2013-04-02 组蛋白去乙酰化酶(hdacs)抑制剂

Country Status (13)

Country Link
US (2) US9387209B2 (enExample)
EP (1) EP2836484B1 (enExample)
JP (1) JP6258918B2 (enExample)
KR (1) KR101781922B1 (enExample)
CN (1) CN104364237B (enExample)
AU (1) AU2013246278B2 (enExample)
BR (1) BR112014025122B1 (enExample)
ES (1) ES2630062T3 (enExample)
IL (1) IL235053A (enExample)
IN (1) IN2014MN02104A (enExample)
RU (1) RU2629947C2 (enExample)
TW (1) TWI481597B (enExample)
WO (1) WO2013154870A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052739B2 (en) 2011-09-12 2018-08-21 Applied Materials, Inc. Carrier head with composite plastic portions
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US10807944B2 (en) 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7254028B2 (ja) * 2017-05-16 2023-04-07 アンジー ファーマスーティカル シーオー．，エルティーディー． ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
KR20210116830A (ko) * 2020-03-17 2021-09-28 충북대학교 산학협력단 신규한 4-옥소퀴나졸린-기반 n-하이드록시프로펜아미드 및 이의 용도
CN111517977B (zh) * 2020-05-28 2023-05-23 爱斯特（成都）生物制药股份有限公司 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法
MX2022015532A (es) * 2020-06-08 2023-04-04 Annji Pharm Co Ltd Inhibidores selectivos de hdac6 y usos de los mismos.
WO2023159155A1 (en) * 2022-02-18 2023-08-24 Pivalent Therapeutics, Inc. Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
CN120379970A (zh) * 2023-10-18 2025-07-25 太溪生技新药股份有限公司 用于hdac抑制的喹唑啉酮衍生物
WO2026099248A1 (en) * 2024-11-06 2026-05-15 Janssen Pharmaceutica Nv N-phenyl-2-(4-oxo-quinazolin-3(4h)-yl)propanamide derivatives as tmem175 modulators for reducing alpha-synuclein aggregation for the treatment of parkinson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054658A (en) * 1974-02-06 1977-10-18 William H. Rorer, Inc. Therapeutic compositions containing methaqualone
CN1708306A (zh) * 2002-11-04 2005-12-14 Nps制药公司 作为钙阻滞剂的喹唑啉酮化合物
CN101263125A (zh) * 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
CN101356160A (zh) * 2005-12-08 2009-01-28 诺瓦提斯公司 作为辣椒素受体拮抗剂的三取代的喹唑啉酮衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE666424A (enExample) * 1965-05-12 1966-01-05
FR6001M (enExample) * 1966-12-02 1968-04-29
ZA705270B (en) * 1969-08-02 1971-04-28 Sumitomo Chemical Co Novel quinazolinone derivatives and a process for production thereof
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JP3488890B2 (ja) * 1993-11-09 2004-01-19 アグロカネショウ株式会社 ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
EP1524262A1 (en) 2000-03-24 2005-04-20 Methylgene, Inc. Inhibitors of histone deacetylase
JP2003528074A (ja) * 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
ITMI20041869A1 (it) 2004-10-01 2005-01-01 Dac Srl Nuovi inibitori delle istone deacetilasi
EA018698B1 (ru) 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0624187D0 (en) 2006-12-04 2007-01-10 Jackson William P HDAC inhibitors
WO2008087514A2 (en) 2007-01-17 2008-07-24 Orchid Research Laboratories Limited Hdac inhibitors
JP2010536876A (ja) 2007-08-21 2010-12-02 アークル インコーポレイテッド Ｈｄａｃインヒビター
CA2700857C (en) 2007-10-01 2016-08-02 John S. Kovach Hdac inhibitors
JP5838157B2 (ja) 2009-07-22 2015-12-24 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ Ｈｄａｃ阻害剤およびそれを用いる治療法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054658A (en) * 1974-02-06 1977-10-18 William H. Rorer, Inc. Therapeutic compositions containing methaqualone
CN1708306A (zh) * 2002-11-04 2005-12-14 Nps制药公司 作为钙阻滞剂的喹唑啉酮化合物
US20060052345A1 (en) * 2002-11-04 2006-03-09 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
CN101263125A (zh) * 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
CN101356160A (zh) * 2005-12-08 2009-01-28 诺瓦提斯公司 作为辣椒素受体拮抗剂的三取代的喹唑啉酮衍生物

Also Published As

Publication number Publication date
AU2013246278A1 (en) 2014-11-13
BR112014025122B1 (pt) 2022-08-16
EP2836484A1 (en) 2015-02-18
EP2836484B1 (en) 2017-06-14
RU2014144142A (ru) 2016-06-10
ES2630062T3 (es) 2017-08-17
US9155739B2 (en) 2015-10-13
IL235053A (en) 2017-09-28
EP2836484A4 (en) 2015-09-02
RU2629947C2 (ru) 2017-09-05
AU2013246278B2 (en) 2016-11-03
KR101781922B1 (ko) 2017-09-26
JP6258918B2 (ja) 2018-01-10
US9387209B2 (en) 2016-07-12
US20150196563A1 (en) 2015-07-16
WO2013154870A1 (en) 2013-10-17
US20130267542A1 (en) 2013-10-10
TW201345898A (zh) 2013-11-16
KR20150000901A (ko) 2015-01-05
TWI481597B (zh) 2015-04-21
IN2014MN02104A (enExample) 2015-09-04
BR112014025122A2 (pt) 2021-07-06
CN104364237A (zh) 2015-02-18
JP2015512939A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
CN104364237A (zh) 组蛋白去乙酰化酶(hdacs)抑制剂
JP7254028B2 (ja) ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤
JP6313416B2 (ja) Ｉｄｏ阻害剤
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
AU2008203305A1 (en) New benzimidazole derivatives
EP3590920B1 (en) 2-(substituted benzene matrix) aromatic formate fto inhibitor, preparation method therefor, and applications thereof
CA2651128A1 (en) Benzimidazole modulators of vr1
HRP20030451A2 (en) Tetralone derivatives as antitumor agents
JP2008056660A (ja) インドールスルフォンアミド化合物
JP2011510917A (ja) 新規ｎ−（２−アミノ−フェニル）−アミド誘導体
CN116354901B (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
JP2020520982A (ja) がん治療のためのイオンチャネル阻害剤化合物
CN114685382B (zh) 具有HDACs抑制活性的喹唑啉-4-胺衍生物及其制备方法与用途
CN112390781B (zh) 二芳基取代的1,1-乙烯类化合物、制备方法及用途
WO2014000694A1 (zh) 苯并杂环衍生物
WO2021093860A1 (zh) 取代的双三环化合物及其药物组合物和用途
CN101821247A (zh) 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物
CN107311986A (zh) 四氢异喹琳‑3‑羧酸类热休克蛋白90抑制剂及其应用
WO2015043487A1 (zh) 喹唑啉类化合物及其制备方法与应用
CN113929635B (zh) 1,6-二苯基-1H-苯并[d][1,2,3]三唑类化合物及其制备方法与用途
CN111533673B (zh) 一种含有缩氨基硫脲/缩氨基脲结构的化合物、其制备方法及医药用途
CN110054619A (zh) 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
CA2461034A1 (en) Tetrahydroisochinolines, their production and the use thereof as analgesics
CN102010425B (zh) 1,4-二硫-7-氮杂螺[4,4]壬烷-8-羧酸衍生物类组蛋白去乙酰化酶抑制剂及其应用
CN104327043B (zh) 一种吖啶硫醚类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Ai Road four Taipei City, Taiwan Chinese Daan District 25 1 Building No. 5

Applicant after: ANNJI PHARMACEUTICAL Co.,Ltd.

Address before: 2, building 12, 1 Guangfu Road South, Songshan District, Taipei, Taiwan, China

Applicant before: Ricky Biotechnology New Pharmaceutical Co.,Ltd.

Address after: Ai Road four Taipei City, Taiwan Chinese Daan District 25 1 Building No. 5

Applicant after: ANNJI PHARMACEUTICAL Co.,Ltd.

Address before: 2, building 12, 1 Guangfu Road South, Songshan District, Taipei, Taiwan, China

Applicant before: ANNJI PHARMACEUTICAL Co.,Ltd.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160630

Address after: 2, building 12, 1 Guangfu Road South, Songshan District, Taipei, Taiwan, China

Applicant after: Ricky Biotechnology New Pharmaceutical Co.,Ltd.

Address before: Ai Road four Taipei City, Taiwan Chinese Daan District 25 1 Building No. 5

Applicant before: ANNJI PHARMACEUTICAL Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant